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Abstract: To overcome both the dose-limiting side effects of conventional chemotherapeutic 
agents and the therapeutic failure resulting from multidrug resistance (MDR) and minimize 
adverse effects of chemotherapy agents, a novel chemotherapy formulation of magnetic nanopar-
ticles co-loaded with daunorubicin and 5-bromotetrandrin (DNR/BrTet-MNPs) was developed, 
and its effect on MDR leukemic cells was explored. After the DNR and Br were co-loaded onto a 
pluronic-stabilized and oleic acid-modified magnetic nanosystem, the physical characteristic and 
drug-loading capacity were evaluated. The cell toxicity of the self-prepared DNR/BrTet-MNPs 
formulation was then determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assay; the cellular uptake of drug was demonstrated by fluorescent microscope. Lastly, 
the transcription of mdr1 and the expression of P-glycoprotein (P-gp) were detected by the reverse 
transcription reaction and western blotting assay, respectively. The results showed that the self-
prepared DNR/BrTet-MNPs formulation possessed a sustained release of drug and displayed a 
dose-dependent antiproliferative activity on MDR leukemia K562/A02 cells. It also enhanced 
the accumulation of intracellular DNR in K562/A02 cells and downregulated the transcription 
of the mdr1 gene and the expression of P-gp. These findings suggest that the remarkable effect 
of the novel DNR/BrTet-MNPs formulation, acting as a drug depot system for the sustained 
release of the loaded DNR and BrTet, on multidrug resistance leukemia K562/A02 cells would 
be a promising strategy for overcoming MDR.
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Introduction
Owing to multidrug resistance (MDR), systematic chemotherapy is limited in 
  leukemia treatment.1 Recent exciting data suggest that the overexpression of adenosine 
triphosphate-dependent drug efflux pump on the surface of tumor cells, P-glycoprotein 
(P-gp/ABCB1), is the main cause of MDR.2 P-gp, coded by the mdr1 gene, effluxes drug 
and decreases intracellular drug dose, which reduces cytotoxicity of antitumor drugs and 
thus induces MDR.3 Therefore, exploiting P-gp inhibitors has the potential of overcoming 
MDR and enhancing chemotherapy efficacy.4 Unfortunately, these compounds are often 
nonspecific and have low efficiency and/or high toxicity; as such, Phase 3 clinical trials 
of these agents are largely disappointing.5–9 Therefore, searching for more efficient and 
lower toxic MDR reversal agents is our main purpose in refractory tumor therapy.
Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid, is the extract component from 
the root of Stephania tetrandra S. Moore (or Fenfangji) in the Menispermaceae family 
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of traditional Chinese herbs.10 A number of   accumulated 
evidences indicate that Tet has been shown to be a Ca2+ chan-
nel antagonist, and it has reversal effect on P-gp-mediated 
MDR.11,12 Moreover, 5-bromotetrandrine (BrTet) is a bro-
mized derivative of Tet, which is more efficient than Tet at 
modulating MDR in vitro.13 Therefore, co-administration 
of conventional chemotherapy with an MDR reversal agent 
enhances their antitumor efficacy and reduces their side 
effects. However, it is necessary to minimize the exposure 
of normal cells to inhibitor and anticancer drugs, and to 
co-localize both of them in the tumor cells. Currently, nano-
technology has shown tremendous progress in target-specific 
delivery of drugs in the body.14 The targeting drug-delivery 
system is far more effective than conventional chemotherapy, 
benefiting from decreasing toxicity of drugs to normal tis-
sues, prolonging circulation half-life in plasma, enhancing 
drug stability, improving aqueous solubility, and increasing 
tumor site selectivity.15,16 Due to their biocompatibility and 
biodegradability, superparamagnetic iron oxide nanoparticles 
have been widely used in various biomedical applications,17 
such as a carrier for anticancer drugs. Daunorubicin (DNR) 
is one of the anthracyclines and a substrate for P-gp,18 which 
is the essential part of first-line chemotherapy in the treat-
ment of many solid and hematological malignancies,19 but 
the clinical use of DNR has been impeded by its serious 
side effects, such as cardiotoxicity and drug resistance.20 To 
overcome both the dose-limiting side effects of conventional 
chemotherapy and the therapeutic failure of MDR, a novel 
drug-delivery formulation, magnetic iron oxide nanoparticles 
co-loaded with DNR and BrTet (DNR/BrTet-MNPs) was 
developed, and its reversal efficacy on K562/A02 cells was 
evaluated in vitro.
Materials and methods
Main drugs and chemicals
The following materials were purchased: DNR hydro-
chloride (DNR⋅HCl) (Huifengda Chemical Co, Ltd, Jinan, 
China); BrTet (Kanghong Phamaceuticals Inc, Chengdu, China); 
doxorubicin (Hisun Phamaceutical Co,   Zhejiang, China); iron 
chloride hexagydrate (FeCl3⋅6H2O), iron sulfate heptahydrate 
(FeSO4⋅7H2O), ammonium hydroxide (NH3⋅H2O), oleic acid 
(OA), and absolute ethanol (Sinopharm Chemical Reagent Co, 
Ltd, Shanghai, China); Pluronic® F-127, 3-(4, 5-  dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich, 
St Louis, MO); 4′, 6-diamidino-2-phenylindole (DAPI) (Beyo-
time Institute of Biotechnology, Shanghai, China); randomly 
primed polymerase chain reaction   (RP-PCR) kit (Takara Bio-
technology, Dalian, China); mouse   monoclonal   anti-human 
P-gp and glyceraldehyde 3-phosphate   dehydrogenase   
(GAPDH) (Santa Cruz Biotechnology, Santa Cruz, CA).
Synthesis of DNR/BrTet-MNPs
According to the authors’ previously described method,21 
OA-coated and pluronic-stabilized iron oxide nanoparticles 
were synthesized, both hydrophobic DNR and hydrophobic 
BrTet were prepared by adding triethylamine into DNR or 
BrTet hydrochloride methanolic solution, and a combina-
tion of DNR/BrTet (w/w = 1:1) was added dropwise into the 
above mentioned aqueous dispersion of MNPs, which was 
being stirred vigorously on a magnetic stirring plate over-
night to make the drug participate into OA layer.22 Finally, 
the product (DNR/BrTet-MNPs) was washed twice with 
deionized water to remove the drug adsorbed on the surface 
of the MNPs. A magnet was put outside of the vial for 
5 hours, which attracted the drug-loaded MNPs, and then 
the liquid was removed carefully. The drug-loaded MNPs 
were then resuspended in deionized water and washed twice 
to obtain the synthesized DNR/BrTet-MNPs.
Physical characteristic measurements
The sample was suspended in water and dropped on a 
carbon-coated copper grid to analyze the morphology of 
OA-coated and pluronic-stabilized iron oxide nanoparticles 
under transmission electron microscope (JEM-2100; JEOL, 
Tokyo, Japan). Meanwhile, the hydrodynamic diameter 
and zeta potential of DNR/BrTet-MNPs were determined 
by dynamic light scattering (ZS90; Malvern Instruments, 
Worcestershire, UK) and zeta plus potential analyzer 
(Brookhaven Instruments, Holtsville, NY), respectively. 
Furthermore, the magnetic properties of drug-loaded MNPs 
were measured using a vibration sample magnetometer 
(VSM) integrated in a physical property measurement 
system (PPMS-9; Quantum Design, San Diego, CA) up to 
50,000 Oe at 300 K.
Studying drug loading and release
To determine DNR loading, less than 2 mg lyophilized drug-
loaded MNPs were dispersed in 2 mL methanolic solution 
(12.5%) in chloroform (v/v). The solution was shaken for 
24 hours and then centrifuged at 16,000 rpm for 10 minutes 
at 4°C. Volumes of 100 µL supernatant were diluted to 
2 mL methanolic-chloroform solution and analyzed using a 
Shimadzu HPLC system (Shimadzu, Kyoto, Japan) at detec-
tion/excitation wavelengths of 480/560 nm. To determine 
BrTet loading, the lyophilized drug-loaded MNPs were 
dispersed in 2 mL methanolic solution and shaken as above; 
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1 mL supernatant was diluted to 4 mL methanolic solution 
and measured at wavelength of 281 nm using an ultraviolet 
spectrophotometer (UV-3600; Shimadzu). The DNR or BrTet 
loading capacity (LC) and encapsulation efficiency (EE) of 
the nanoparticles were calculated as:
  LC = W e/Wp × 100%  (1)
and
  EE = W e/Wt × 100%  (2)
where W e is the amount of DNR or BrTet encapsulated in 
nanoparticles, Wp is the weight of drug-loading MNPs, and 
Wt is the total amount of DNR or BrTet added.
For the in vitro drug release study, a certain amount of 
lyophilized drug loaded-MNPs were dispersed in 2.5 mL 
Tween®-PBS (phosphate buffered saline) (pH = 7.4, contain-
ing 0.1% w/v Tween-80), and then placed in a dialysis mem-
brane bag with a molecular weight cutoff of 8000–14,000 
Da. The bag was bathed in a tube with 2.5 mL Tween-PBS 
solution, and the tube was incubated in a shaking water 
bath at 37°C. The buffer was withdrawn at different time 
intervals and complemented with the fresh buffer. The 
amount of DNR and that of BrTet in buffer were analyzed as   
above.
Cell culture
Human chronic myeloid leukemia resistant cell line to doxo-
rubicin, K562/A02, was received as a gift from the Institute 
of Hematology, Chinese Academy of Medical   Sciences. 
Cells were cultured in RPMI (Roswell Park Memorial 
Institute) 1640 medium containing 10% heat-inactivated 
newborn bovine serum, 10 mM HEPES (4-[2-hydroxyethyl]-
1-piperazineethanesulfonic acid), 100 U/mL penicillin, and 
100 µg/mL streptomycin at 37°C in a humidified 5% CO2 
incubator. For maintaining MDR phenotype, K562/A02 was 
cultured in the medium containing 1 µg/mL doxorubicin at 
least 1 week before use.
Cytotoxicity assay
K562/A02 cells were plated at a density of 20,000 cells per 
well in 96-well plates. Different concentrations of DNR alone 
or its combination with MNPs (0.1–50.0 µg/mL), and co-
administration of DNR and BrTet (DNR:BrTet = 1:1 w/w) or 
MNPs (0.05–20.00 µg/mL) were added. After treatment for 
48 hours, 20 µL MTT solution (5 mg/mL) was added to each 
well and incubated for another 4 hours at 37°C, the formazan 
salts were dissolved with 150 µL dimethyl sulfoxide, and the 
absorbance at 450 nm was   measured using a microplate reader 
(Multiskan MK3; Thermo   Scientific, Boston, MA). The cell 
viability was calculated as (ODtreated group/ODcontrol group) × 100%, 
and half-maximal inhibitory concentration (IC50) values were 
calculated.
Fluorescence microscope
K562/A02 cells were collected and smeared after being 
cultured as above. The cells were fixed with methanol for 
15 minutes and then stained with fluorochrome dye DAPI. 
Morphologic characteristics were observed under a fluores-
cence microscope (X51; Olympus, Tokyo, Japan), with a 
peak excitation wavelength of 340 nm.
Intracellular DNR accumulation  
with rhodamine 123 staining
Rhodamine 123 (R123), cellular accumulation of P-gp 
substrate, was examined to evaluate the function of P-gp 
of K562/A02 cells. In brief, after being treated as above, 
K562/A02 cells were washed with ice-cold PBS and then 
incubated with 100 µg/L R123 for 60 minutes. After being 
washed and suspended in 500 µL PBS, each sample was 
determined using a flow cytometer at excitation/emission 
wavelengths of 488/575 nm. The relative R123 fluorescence 
intensity (FI) was calculated as FItreated group/FIcontrol group. Those 
cells treated with RPMI 1640 alone were used as negative 
control.
RT-PCR analysis of mdr1 mRNA
The K562/A02 cells were incubated as above. Total 
RNA extraction was conducted with TRIzol® (Invit-
rogen, Carlsbad, CA), and RT-PCR was performed 
according to   manufacturer’s instructions. The reverse 
transcription reactions were performed using TaKaRa 
RNA PCR Kit as previously described.23 The designed 
PCR primers included the mdr1 primers   (forwards 
5′-TGGTTTGATGTGCACGATGTTGGG-3′, reverse 
5′-AGATCAGCAG GAAAGCAGCACCTA-3′) and the 
GAPDH primers (forwards 5′-GCCACATCGC TCAGA-
CAC-3′, reverse 5′-CATCACGCCACAGTTTCC-3′). The 
amplified PCR products were 436 bp for mdr1 and 614 bp 
for GAPDH. The newly synthesized cDNA was amplified 
by PCR, and the conditions were 94°C for 30 seconds, 
56°C for 30 seconds, and 72°C for 1 minute. There was 
pre-denaturing at 94°C for 2 minutes and final extension at 
72°C for 7   minutes. The obtained PCR products were visual-
ized on 1.5% agarose gels with ethidium bromide staining, 
and densitometry analysis was performed using ScnImage 
software (Scion Corporation, Frederick, MD).
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Western blotting assay
K562/A02 cells were incubated as above. The harvested 
cells were lysed in lysis buffer containing 25 mM Tris-HCl 
(pH = 7.4), 150 mM NaCl, 1% Triton® X-100, 5 mM EDTA 
(ethylenediaminetetraacetic acid), 5 mM EGTA (ethylene 
glycol tetraacetic acid), 10 mM NaF, 1 mM phenylmethane-
sulfonylfluoride, 0.5% NP-40, 10 µg/mL aprotinin, 10 µg/mL 
leupeptin, and 1 mM pepstatin for 15 minutes at 4°C, then 
centrifuged at 10,000 rpm for 5 minutes. The supernatant 
was collected and the amount of protein was measured using 
Bio-Rad protein assay (Bio-Rad, Hercules, CA). Samples 
containing 25 µg protein were separated by 10% SDS-PAGE 
(sodium dodecyl sulfate polyacrylamide gel   electrophoresis) 
and then electro-transferred onto nitrocellulose filter. Five 
percent nonfat milk was used to block the nonspecific bind-
ing sites for 1 hour. Mouse monoclonal anti-human P-gp 
(1:200) or GAPDH (1:400) antibodies were incubated to 
the membrane overnight at 4°C, followed by horserad-
ish peroxidase-labeled rabbit-mouse immunoglobulin G 
(1:5000) as a secondary antibody. The blots were calculated 
by densitometry scans (ECL system, Amersham, UK) accord-
ing to manufacturer’s instructions.
Statistical analysis
All the data were expressed as mean ± standard deviation, 
and analyzed using SPSS software (v 13.0; SPSS Inc, 
Chicago, IL). Differences among various groups were evalu-
ated using one-way analysis of variance. All the reported 
P values were two-tailed, and those ,0.05 were considered 
to be statistically significant.
Results
Physical characteristics of drug-loaded 
magnetic nanoparticles
The range of magnetic iron oxide nanoparticles was 10–20 nm, 
and the clusters of nanoparticles resulting from dehydration 
were also observed in local fields under transmission electron 
microscopy. The lattice structure of iron oxide nanoparticles 
under high-resolution electron microscope demonstrated that the 
nanoparticles were composed of magnetite (Fe3O4)   ( Figure 1A). 
The synthesized DNR/BrTet-MNPs yielded a hydrodynamic 
average size of 135 nm with polydispersity index of 0.185 by 
dynamic light scattering (Figure 1B). The zeta potential of 
DNR/BrTet-MNPs in water was −27.02 ± 0.75 mV , and the 
drug-loaded MNPs were superparamagnetic with a saturation 
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Figure 1 Physical characteristic of drug-loaded magnetic nanoparticles. (A) The nanoparticles under the transmission electron microscope. (B) Hydrodynamic particle size 
distribution of DNR/BrTet-loaded MNPs by Malvern Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). (C) Magnetizaion as a function of field drug-loaded 
iron oxide nanoparticles by a vibration sample magnetometer. (D) Release of DNR and BrTet from MNPs under in-vitro conditions.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2126
Cheng et alInternational Journal of Nanomedicine 2011:6
Table  1  Drug  loading  of  DNR  and  BrTet  in  MNPs  (n  =  3, 
mean ± standard deviation)
DNR (% w/w) BrTet (% w/w) Total drug  
loading (% w/w) Added Loaded Added Loaded
0.0 0.0 10.0 6.15 ± 0.65 6.15 ± 0.65
5.0 4.60 ± 0.39 5.0 3.65 ± 0.80 8.25 ± 1.13
10.0 7.62 ± 0.47 0.0 0.0 7.62 ± 0.47
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic 
nanoparticle.
Table 2 Effect of MNPs and BrTet on K562/A02 cells for 48 hours 
(n = 3, mean ± standard deviation)
MNPs BrTet
Concentration  
(μg/mL)
Relative  
growth  
rate (%)
Concentration  
(μg/mL)
Relative  
growth  
rate (%)
6.25 97.12 ± 1.31 0.1 103.46 ± 2.09
12.5 89.06 ± 0.36 0.5 105.02 ± 2.78
25 84.45 ± 1.24 1 102.95 ± 2.54
50 85.87 ± 4.50 2   91.87 ± 1.98a
100 81.79 ± 1.91b 5   14.02 ± 2.04
Notes: aRelative growth rate was more than 90% when BrTet was less than 2 µg/mL. 
bRelative growth rate was more than 80% when MNPs alone was less than 100 µg/mL.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNPs, magnetic 
nanoparticles.
magnetization (Ms) of 51.31 emu/g magnetic and coercivity 
(Hc) of 15.67 Oe by VSM (Figure 1C).
Drug loading and release
Drug-loading capacity and encapsulation efficiency are shown 
in Table 1. The released behavior of DNR/BrTet-MNPs in 
Tween-PBS solution at 37°C was shown in   Figure 1D. The 
common burst release of DNR and BrTet were both observed 
in the first 5 days, of which about 48% was for DNR and 
37% for BrTet. Interestingly, the drug-loaded MNPs were 
able to release drugs sustainably until 25 days.
In vitro cytotoxicity on K562/A02  
cells of drug-loaded MNPs
When incubated with MNPs (less than 100 µg/mL) or 
BrTet (less than 2 µg/mL) for 48 hours, obvious cytotoxic 
effects on K562/A02 cells were not observed (Table 2). 
Both DNR alone and in combination with MNPs signifi-
cantly inhibited the growth of K562/A02 cells, and the IC50 
values were 19.11 ± 1.05 µg/mL and 10.71 ± 0.62 µg/mL, 
respectively. Notably, when DNR was co-administrated with 
BrTet (DNR: BrTet = 1:1 w/w), the cytotoxicity to K562/
A02 cells was significantly enhanced and the IC50 value 
was 1.01 ± 0.17 µg/mL. DNR/BrTet-co-loaded MNPs also 
displayed a dose-dependent antiproliferative activity, and the 
IC50 value was 8.40 ± 1.26 µg/mL (Figure 2).
Fluorescent microscope for cellular 
uptake of drug
After incubation for 48 hours, high red fluoresce from DNR 
was seen localized in the cytoplasm of cells treated with 
DNR alone or DNR-MNPs, indicating that cells endocytosed 
and/or pinocytosed free DNR or DNR-MNPs (Figure 3A 
and B). When being combined with BrTet, a prominent 
increased red fluorescence was observed in the nucleus 
(Figure 3C). The nuclear and cytoplasm localization of 
DNR was observed in cells treated with DNR/BrTet-MNPs 
(Figure 3D).
Function of P-gp in K562/A02 cells
R123 uptake was increased in K562/A02 cells treated with 
either BrTet alone or DNR/BrTet compared with DNR alone, 
and the increase was also observed in cells treated with 
either BrTet-MNPs or DNR/BrTet-MNPs compared with 
DNR-MNPs (P , 0.05). In addition, there were significant 
differences among BrTet, DNR/BrTet, BrTet-MNPs, and 
DNR/BrTet-MNPs (P , 0.05) (Figure 5).
Expression of mdr1/P-gp  
in K562/A02 cells
Compared with control group, the transcriptions of mdr1 mRNA 
were significantly downregulated by nearly 26% in the combi-
nation of DNR with BrTet (DNR/BrTet l) group and by 13% 
in the DNR/BrTet-MNPs group (P , 0.05) (Figure 5A). The 
levels of P-gp were significantly downregulated by nearly 42% 
in the DNR/BrTet group and by 32% in DNR/BrTet-MNPs 
group (P , 0.05) (Figure 4B).
Discussion
Currently, systemic chemotherapy is still the main treatment 
option for hematologic malignancies, but the disturbing fact 
is that drug-resistant cells usually lead to therapeutic failure. 
MDR is a multifactorial problem involving several genes act-
ing either alone or in concert with other factors. For example, 
the increased expression of MDR1 drug transporter gene cod-
ing for P-gp pump, MDR-related protein, and topoisomerase 
II has been associated with the MDR phenotype.24 A lot of 
chemotherapeutic agents such as anthracyclines or paclitaxel 
have been proved to be capable of inducing drug resistance 
via overexpression mdr1/P-gp pathway,25 which is one of the 
major mechanisms of MDR. Although several MDR reversal 
agents have been applied in laboratory studies and clinical 
  trials, there is still no significant improvement. Notably, 
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Figure 3 Subcellular distribution of DNR in K562/A02 cells treated with DNR alone, DNR-MNPs, DNR/BrTet, and DNR/BrTet-MNPs under fluorescence microscope.
Abbreviations: DNR, daunorubicin; BrTet, 5-bromotetrandrin; MNP, magnetic nanoparticle.
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BrTet, an excellent reversal of P-gp mediated MDR,23,26 sig-
nificantly enhanced the anticancer activity of doxorubicin in 
vitro by inhibiting the overexpression of P-gp.27
To overcome drug resistance and reduce the side effects 
during chemotherapy, nanotechnology holds promising 
potential, utilizing targeted drug delivery. In this study, the 
ability of a novel chemotherapy formulation (DNR/BrTet-
MNPs) to overcome P-gp-mediated drug resistance in K562/
A02 cells was investigated, and the efficacy evaluated. First, 
an anticancer drug and a MDR reversal agent were encapsu-
lated in the pluronic-OA-iron oxide nanoparticles, which are 
roughly spherical from 135 nm and have superparamagnetic 
with Ms of 51.31 emu/g magnetic and Hc of 15.67 Oe. In 
this formulation, DNR and BrTet are stored in the OA shell 
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and released sustainably, where OA acts as a drug depot and 
Pluronic F-127, an amphiphilic synthetic polymer, is used to 
improve aqueous dispersity of the formulation, which makes 
the nanoparticles disperse well in water and prolongs the 
systemic circulation time and increases eventual localization 
efficiency of the drug-delivery system to the tumor site.28 In 
addition, it also acts as a drug depot system for the sustained 
release of drug and ensures effective dose in targeted tissue 
and reduces damage to other organs. Compared with co-
administration of a P-gp inhibitor and an anticancer drug,29 
in this present study the adoption of nanoparticles in the 
drug-delivery system made it possible for two drugs with 
different pharmacokinetics and tissue disposition to play 
roles at the same time and same place.
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Next, the effects of the formulation of a nanoparticle 
delivery system for overcoming drug-resistant K562/A02 in 
vitro was tested. In the present study, only about 19% of 
DNR and 16% of BrTet are released from MNPs in the first 
2 days. The efficacy of DNR/BrTet-MNPs on K562/A02 cells 
at 48 hours was lower than that of DNR-BrTet, which may 
be down to the sustained release of drugs. Meanwhile, it is 
found that DNR/BrTet-MNPs show significant antiprolifera-
tive activity compared with DNR-MNPs, which is due to the 
reserve effect of BrTet. It is reasonable to see that red fluores-
cence intensity was primarily accumulated in the cytoplasm 
of K562/A02 cells treated with either DNR or DNR-MNPs, 
once DNR was co-administered with BrTet; red fluorescence 
intensity was increased significantly in the nucleus of K562/
A02 cells, indicating BrTet makes the increase of intracellular 
DNR accumulation through inhibiting the drug efflux pumps 
on the cell membrane, such as P-gp, and then DNR further 
diffuses into the nucleus. Interestingly, red fluorescent light 
both in the cytoplasm and nucleus was observed in K562/
A02 cells treated with DNR/BrTet-MNPs, suggesting that 
DNR and BrTet are released slowly from the nanoparticles 
in the cytoplasm after being taken up by cells, and then DNR 
slowly diffuses into the nucleus. Thus, the authors considered 
that DNR/BrTet-MNPs act as an intracellular depot system 
and promote sustained drug retention.
P-gp has been demonstrated to significantly reduce the 
toxicity of anticancer drugs by influencing their pharmacoki-
netics and pharmacodynamics.13 The present study clearly 
revealed that the transcription of mdr1 and expression of P-gp 
were both downregulated in K562/A02 cells after incubation 
with either DNR/BrTet-MNPs or DNR/BrTet for 48 hours. 
The results of R123 uptake suggested that BrTet obviously 
inhibited the efflux of R123 by P-gp both in solution and in 
MNPs. Moreover, the accumulation of R123 in both BrTet 
and BrTet-MNPs groups was found to be lower than that in 
both DNR/BrTet-MNPs and DNR/BrTet. The possible expla-
nation is that the decrease of R123 accumulation means cells 
treated with DNR/BrTet-MNPs or DNR/BrTet are undergoing 
apoptosis, for R123 is a fluorescent probe for monitoring the 
membrane potential of mitochondria.30 In summary, these 
results indicate that a combination of DNR and BrTet with 
or without MNPs prevent the development of mdr1 pheno-
type in K562/A02 cells in vitro. But the effect has not been 
observed by DNR in nanoparticles, which is to some extent 
controversial to that reported by Jain et al; in their study, 
doxorubicin loaded with nanoparticles showed antitumor 
efficacy on tumor cells.30,31 These opposing results suggest 
that there may be fundamental differences between cell types 
and the characteristic of sustained release of the formulation 
used in this study. Importantly, this novel magnetic iron oxide 
nanoparticle formulation co-loading DNR and BrTet with 
the excellent property of sustained release is superior to the 
prior polymerized MNPs with DNR and BrTet.23 All of these 
findings suggest the novel magnetic iron oxide nanoparticle 
formulation co-loading DNR and BrTet may be a successful 
platform to overcome MDR.
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Figure 5 Transcription of mdr1 and expressions of P-gp in K562/A02 cells. (A) Transcription of mdr1 mRNA by RT-PCR; (B) expression of P-gp by western blotting assay.
Note: *P , 0.05, when compared with control group.
Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MNP, magnetic nanoparticle; P-gp, P-glycoprotein; 
RT-PCR, reverse transcriptase polymerase chain reaction.
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Conclusion
The remarkable effect of the novel DNR/BrTet-MNPs 
  formulation, acting as a drug depot system for the sustained 
release of the loaded DNR and BrTet on multidrug resistance 
leukemia K562/A02 cells would be a promising strategy for 
overcoming MDR.
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